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Abstract: Introduction: Post-transplant lymphoproliferative disorder is a life-threatening complication of solid 
organ transplantation. In pediatric recipients, PTLD has been reported in 6.4%-19.5% of lung, heart and heart-lung 
transplants, 4-15% of liver transplants and 1.2-10.1% of kidney transplants. Although most lymphomas typically 
occur in lymph nodes, extranodal involvement is also common.  The aim of our study was to determine the site and 
symptoms of PTLD in children who underwent liver transplantation during 2009-2012 in Liver Transplantation 
Center of Nemazee Hospital. Material and methods: This study is a cohort study on existing data of children who 
received liver transplant between Juanury 2009 and December 2012 at Liver Transplant Center of Nemazee Hospital 
in Shiraz. During the study period, the PTLD occurrence was assessed in follow up visits, if the diagnosis of PTLD 
was confirmed the affected patient was entered the study and additional information was obtained. The diagnosis of 
PTLD was considered in patients with fever of undetermined origin, lymphadenopathy, allograft dysfunction, and 
pulmonary infiltrates. The data was analyzed using SPSS software ver.18. Statistical descriptive methods, Chi 
square test, and independent t-test,  were used for analyzing the data. P value smaller than 0.05 were considered 
significant. Results: Totally, 203 children undergoing liver transplant surgery were evaluated. The age range of 
patients was 8 months to 18 years with mean of 8.8±5.6 years old. In our study 17 (8.4%) patients developed PTLD. 
The mean interval between transplantation and PTLD diagnosis was 8.4 ±5.61 months ranging from 4 to 24 months. 
A total of five patients (2.5%) died during the follow-up period and all of them were PTLD affected children (29.4% 
of PTLD patients). Lymph nodes were the most predominant site involved (64.7%), while liver and GI involved in 
35.2%. Conclusion: The results of this study emphasize the relatively high incidence of PTLD after liver 
transplantation in children. Because of its impact on patient’s outcome and reducing recipient’s survival, it is 
important to minimize this problem by early diagnosis and providing effective treatment. 
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Introduction: 
Post-transplant lymphoproliferative disorder 
refers to an uncontrolled proliferation of lymphocytes 
within the context of immunosupression after solid 
organ or bone marrow transplantation (1, 2). PTLD is 
a major graft and  also life-threatening complication of 
solid organ transplantation that includes a spectrum of 
disorders ranging from benign hyperplasia to invasive 
lymphoma(2, 3). Ebstein-Barr virus (EBV) is an 
important factor in the pathogenesis of PTLD .The 
risk for EBV is thought to result from community 
contact or transmission of EBV from the donor organ 
and blood products. Different factors affects the risk 
of PTLD for an individual recipient: the organ 
transplanted, cumulative dose of immunosuppression, 
and age of recipient(4)  .PTLD is seen in up to 10% of 
all solid organ transplant recipients(5). Its incidence is 
higher in children ranging from 1.2% to 30% 
depending on the immunosuppressive regimen used 
and the type of transplanted organ (6). In paediatric 
recipients, PTLD has been reported in 6.4%-19.5% of 
lung, heart and heart-lung transplants, 4-15% of liver 
transplantas and 1.2-10.1% of kidney transplants (3). 
In children PTLD is the most common malignancy 
after organ transplantation and in adults it is the 
second most common malignancy after skin cancer 
(7). In both children and adults  PTLD is the most 
common cause of mortlity due to cancer  after solid 
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organ transplantation and its reported overall mortality 
exceeds  50% (3). According to World Health 
Organization Classification of Tumors, there are 
several distinct categories of PTLD: early lesion 
(Plastic hyperplasia, infectious mononucleosis-like 
PTLD), polymorphic PTLD, monomorphic PTLD (B 
and T/NK cell types), and classical Hodgkin 
lymphoma (1). The clinical presentation of PTLD is 
very variable. Some patients stay symptomless, in 
others non specific symptoms such as malaise, fever 
and weight loss might be appeared. Sometimes the 
clinical presentation of PTLD can resemble infectious 
mononucleosis, especially in children (1). Although 
most lymphomas typically occur in lymph nodes, 
extranodal involvement is also common. Although 
any site can be envolved, gastrointestinal and CNS 
involvement are more common (8). PTLD can also 
involve the allograft itself and rarely can be presented 
as fever without any localizing features (2). The aim 
of our study was to determine the site and symptoms 
of PTLD in children who underwent liver 
transplantation during 2009-2012 in Liver 
Transplantation Center of Nemazee Hospital. 
 
Material and methods: 
This study is a cohort study on existing data of 
children who received liver transplant between 
Juanury 2009 and December 2012 at Liver Transplant 
Center of Nemazee Hospital in Shiraz, the only 
pediatric liver transplantation in Iran. The proposal of 
this study was approved in vice chancellor for 
Research and Technology of Medical University of 
Shiraz. Written and informed consent was obtained 
from all patients’s parents. Also the confidentiality of 
information managed carefully by researchers. All the 
patients who have been referred to this hospital during 
this three year were entered the study. The Inclusion 
criteria were the age of less than 18 years and 
conduction of liver transplantation. The exclusion 
criteria was death due to post-surgical complications 
within the first week after transplantation. The patients 
were referred to this center after necessary 
examinations by pediatric gastroenterologists. Before 
transplantation surgery all of the children were 
evaluated for infections like hepatitis A, B And C, 
HIV, EBV and CMV. Other evaluations such as 
ultrasound or computed tomography were done if the 
child had any related sign or symptoms. During the 
study period, the PTLD occurrence was assessed in 
follow up visits, if the diagnosis of PTLD was 
confirmed the affected patient was entered the study 
and additional information was obtained. The 
diagnosis of PTLD was considered in patients with 
fever of undetermined origin, lymphadenopathy, 
allograft dysfunction, and pulmonary infiltrates. The 
diagnosis of PTLD was confirmed by tissue biopsy 
according to published criteria (9). The data was 
analyzed using SPSS software ver.18. Statistical 
descriptive methods, Chi square test, and independent 
t-test, were used for analyzing the data, P value 
smaller than 0.05 were considered significant. 
 
Results: 
Totally,203 children undergoing liver transplant 
surgery were evaluated. The age range of patients was 
8 months to 18 years with mean of 8.8±5.6 years old. 
Eighty-two (40%) patients were female and 121 
(60%) were male. The most prevalent underlying 
diseases that led to liver transplantation were biliary 
atresia in 29 (14.3%), tyrosinemia in 25 (12.3%), 
cryptogenic cirrhosis in 25 (12.3%), Crigler-Najjar in 
24 (11.8%), PFIC (Progressive Familial Intrahepatic 
Cholestasis) in 22 (10.8%) and Wilson’s disease in 21 
(10.3%) children.In our study 17 (8.4%) patients 
developed PTLD. The mean interval between 
transplantation and PTLD diagnosis was 8.4 ±5.61 
months ranging from 4 to 24 months. The time of 
PTLD diagnosis in these seventeen patients were 
shown in figure 1.Eight PTLD patients (41.7%) were 
male and nine patients (52.9%) were female, this 
difference was not statistically significant (p value = 
0.38).A total of five patients (2.5%) died during the 
follow-up period and all of them were PTLD affected 
children (29.4% of PTLD patients).Of these five 
children three (60%) were male and two (40%) were 
female and the difference between two genders was 
not significant (p value: 0.49).The mean time to PTLD 
diagnosis in expired and alive patients were 11.40±7.9 
and 7.25±4.1 months,respectively (p value: 0.17).The 
location of PTLD are shown in Table1.Lymph nodes 
were the most predominant site involved (64.7%) , 
while liver and GI involved in 35.2% .Of those 
patients who had expired two (40%) had liver 
involvement and three other patients (60%) had 
submandibular lymph node involvement. 
 
Discussion: 
In our study the incidence of PTLD in liver 
transplant recipients was 8.4%.The incidence of PTLD 
has been reported in various studies and its risk 
depends on the type of organ transplant and the age of 
recipients.In adult recipients PTLD has been reported 
to occure in 1-2.8% of liver transplant while the 
incidence of PTLD is significantly higher in 
children(10-12).The rate of PTLD in our study is 
similar to PTLD incidence from other studies ranging 
from 3.8% to 10.7% in paediatric recipients(3, 13, 
14).The incidence of PTLD would be expected to 
increase with the duration of observation.Although 
PTLD may happen at any time after 
transplantation,the risk of PTLD development is 
highest within the first year and reduces over time 
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thereafter(3, 15).Our findings is concordant with other 
studie (12, 13, 16) as most of the PTLD cases (88%) 
occurred during the first year after liver 
transplantation, but in one study only one-third of 
PTLD patients were diagnosed during the first year 
after transplantation, although it has been reported that 
this lower rate can be  as a cause of underreporting 
bias especially in early-stage PTLD(6).The mortality 
rate of PTLD patients in our study was 29.4% that is 
lower than some other studies that has reported 60% 
mortality in child recipients.This difference may be as 
a consequence of improvement in patients care over 
time and differences in immunosuppressive drugs(13), 
but our findings is consistent with more recent studies 
that has reported the death rate about 25% within the 
first year after diagnosis of PTLD(17).The majority of 
PTLD patients in our study had lymph node 
involvement, liver and GI were the second frequent 
site involved.In other studies the lymph node and liver 
were the most affected sites and other organs included 
bowel, lung, kidney, mediastinum, bone marrow and 
CNS(3, 12, 13).The results of this study emohasizes 
the relatively high incidence of PTLD after liver 
transplantation in children.Because of its impact on 
patients outcome and reducing recipients survival, it is 
important to minimize this problem by early diagnosis 
and providing effective treatment.  
 
 
Figure 1. Interval between transplantation and PTLD diagnosis. 
 
Table1. Location of PTLD involvement. 
Location Frequency Percent 
Lymph node:   
 Submandibular 9 52.9 
     Para aortic 1 5.9 
Auxillary 1 5.9 
Liver 3 17.6 
GI 3 17.6 
Total 17 100 
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